What is the recommended dosage of Foracort (fluticasone propionate + formoterol) for bronchial asthma?

Foracort Dosage in Bronchial Asthma

For adults and adolescents ≥12 years with moderate-to-severe persistent asthma, start Foracort (fluticasone/formoterol) at 250/10 mcg twice daily; for mild-to-moderate persistent asthma, use 100/10 mcg twice daily. The specific dose depends on asthma severity and prior treatment, following a stepwise approach where combination ICS/LABA therapy is indicated at Step 3 or higher.

Dosing by Asthma Severity

Step 3 (Mild-to-Moderate Persistent Asthma)

• Foracort 100/10 mcg: 2 inhalations twice daily
• This provides low-dose ICS (fluticasone 200 mcg/day) plus LABA
• Preferred over medium-dose ICS monotherapy 1, 2

Step 4 (Moderate-to-Severe Persistent Asthma)

• Foracort 250/10 mcg: 2 inhalations twice daily
• This provides medium-dose ICS (fluticasone 500 mcg/day) plus LABA
• The preferred treatment at this step 1

Step 5 (Severe Persistent Asthma)

• Foracort 500/20 mcg: 2 inhalations twice daily (adults only)
• This provides high-dose ICS (fluticasone 1000 mcg/day) plus LABA
• Consider adding additional controllers like omalizumab if allergic asthma 1, 2

Key Clinical Evidence

The combination demonstrates superior efficacy compared to either component alone. Clinical trials show fluticasone/formoterol 250/10 mcg twice daily produces greater improvements in FEV1, asthma control, and symptom-free days than fluticasone or formoterol monotherapy 3. The combination is non-inferior to budesonide/formoterol and demonstrates comparable efficacy to fluticasone/salmeterol 4, 5.

Formoterol provides rapid bronchodilation with onset within 5 minutes, making this combination advantageous when quick symptom relief is needed alongside maintenance therapy 6. This is faster than salmeterol-containing combinations 5.

Critical Safety Considerations

Never use Foracort as monotherapy—LABAs must always be combined with ICS. The FDA issued a black-box warning after trials showed increased severe exacerbations and asthma-related deaths when LABAs were used without ICS 1, 2. This warning has since been removed for ICS/LABA combinations, but the principle remains: formoterol should never be prescribed alone for asthma.

Maximum daily formoterol dose should not exceed 24 mcg (equivalent to 4 inhalations of the 10 mcg strength twice daily) 2, 6. Higher doses increase cardiovascular risks including tachycardia, QTc prolongation, and hypokalemia without additional therapeutic benefit 6.

Administration Technique

• Administer twice daily (morning and evening), approximately 12 hours apart
• Use with or without a spacer device depending on the specific inhaler formulation
• Rinse mouth after each use to reduce local side effects (oral candidiasis, dysphonia) 2
• Do not eat, drink, or rinse for 30 minutes after administration to maximize drug deposition

Monitoring and Adjustment

Assess control every 2-6 weeks initially, then every 1-6 months once stable 2. If using SABA more than 2 days per week for symptom relief (excluding exercise-induced bronchospasm prevention), this indicates inadequate control requiring step-up therapy 1.

Step down therapy after 3 months of good control. Real-world evidence shows stepping down from fluticasone/formoterol 1000/40 mcg to 500/20 mcg maintains asthma control in stable patients 7. However, exercise caution in patients with exacerbations in the preceding 12 months, as they have higher risk of exacerbation after step-down 7.

Real-World Effectiveness

Meta-analysis of observational studies shows a severe exacerbation rate of 7-11% with fluticasone/formoterol in real-world settings, with 60.6% of patients achieving asthma control 8. The odds of achieving control increase 2.2-fold compared to pre-treatment conditions 8.

The combination reduces bronchial hyperreactivity and PEF variability more effectively than higher-dose ICS alone with as-needed LABA 9. This effect persists during follow-up with the fixed combination but diminishes when components are used separately.

Common Pitfalls to Avoid

• Do not use Foracort for acute symptom relief—prescribe separate SABA for rescue therapy 2
• Do not increase frequency beyond twice daily—if control is inadequate, step up to higher strength or add additional controller 1
• Monitor growth in children—ICS can suppress growth velocity, though clinical significance remains unclear 2
• Check adherence and inhaler technique before escalating dose—poor technique accounts for many treatment failures 2, 10